WO2012047674A2 - Procédés et compositions pour le traitement de maladie en utilisant l'inhalation - Google Patents

Procédés et compositions pour le traitement de maladie en utilisant l'inhalation Download PDF

Info

Publication number
WO2012047674A2
WO2012047674A2 PCT/US2011/053513 US2011053513W WO2012047674A2 WO 2012047674 A2 WO2012047674 A2 WO 2012047674A2 US 2011053513 W US2011053513 W US 2011053513W WO 2012047674 A2 WO2012047674 A2 WO 2012047674A2
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
agents
calcitriol
inhibitors
therapeutic
Prior art date
Application number
PCT/US2011/053513
Other languages
English (en)
Other versions
WO2012047674A3 (fr
Inventor
David A. Byron
Alan B. Watts
Robert O. Cook
Murat Aydin
Original Assignee
Microdose Therapeutx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microdose Therapeutx, Inc. filed Critical Microdose Therapeutx, Inc.
Priority to EP11831316.2A priority Critical patent/EP2621588A4/fr
Priority to JP2013530423A priority patent/JP2013538830A/ja
Priority to CA2812952A priority patent/CA2812952A1/fr
Publication of WO2012047674A2 publication Critical patent/WO2012047674A2/fr
Publication of WO2012047674A3 publication Critical patent/WO2012047674A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates generally to the field of treating pulmonary diseases comprising the administration of therapeutic agents using inhalation devices.
  • the disclosure has particular utility in connection with the deliver)' of powdered medications to a patient, and will be described in connection with such utility, although other utilities are contemplated.
  • the present invention relates to novel dosage forms and compositions for treating pulmonary diseases, including but not limited to, complications such as corticosteroid resistance.
  • the present invention is also related to improving underlying physiological dysfunction contributing to pulmonary disease.
  • the present invention provides effective administration of therapeutic agents to specific airways of the lungs by utilizing controlled site delivery.
  • Pulmonary disease is any disease or disorder that causes the lungs not to function properly.
  • pulmonary/lung diseases There are three main types of pulmonary/lung diseases and they are generally categorized as airway diseases, lung tissue diseases, and lung circulation diseases.
  • Airway diseases affect the tubes (airways) that cany oxygen and other gases into and out of the lungs. These diseases usually cause a narrowing or blockage of the airways. They include asthma, emphysema, and chronic bronchitis. People with airway diseases sometimes describe the feeling as "trying to breathe out through a straw.” Lung tissue diseases affect the structure of the lung tissue. Scarring or inflammation of the tissue makes the lungs unable to expand fully ("restrictive lung disease"). This makes it hard for the lungs to breathe in oxygen and release carbon dioxide. Pulmonary fibrosis and sarcoidosis are examples of lung tissue diseases. People sometimes describe the feeling as "wearing a sweater or vest that is too-tight" that won't allow them to take a deep breath. Lung circulation diseases affect the blood vessels in the lungs and they are caused by clotting, scarring, or inflammation of the blood vessels. Lung circulation diseases consequently affect the ability of the lungs to take up oxygen and to release carbon dioxide and may also affect heart function.
  • Pulmonary disease includes, but is not limited to, acute bronchitis, acute respiratory distress syndrome (ARDS), asbestosis, asthma, atelectasis, aspergillosis, bronchiectasis, bronchiolitis, bronchopulmonary dysplasia, byssinosis, chronic bronchitis, coccidiomycosis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, emphysema, eosinophilic pneumonia, hantavirus pulmonary syndrome, histoplasmosis, human metapneumovirus, hypersensitivity pneumonitis, influenza, lung cancer, lymphangiomatosis, mesothelioma, necrotizing pneumonia, nontuberculosis Mycobacterium, pertussis, pleural effusion, pneumoconiosis, pneumonia, primary ciliary dyskinesia, primary pulmonary hypertension, pulmonary arterial hypertension, pulmonary fibrosis, pulmonary
  • COPD chronic respiratory disease
  • Symptoms are productive cough and dyspnea that develop over years; common signs include decreased breath sounds, prolonged expiratory phase of respiration, and wheezing. Severe cases may be complicated by weight loss, pneumothorax, frequent acute decompensation episodes, right heart failure, and acute or chronic respiratory failure. Diagnosis is based on history, physical examination, chest x- ray, and pulmonary function tests. Treatment is with bronchodilators. corticosteroids, and, when necessary, 0 2 and antibiotics. About 50% of patients die within 10 years of diagnosis.
  • COPD is also manifested outside of the airways by extra-pulmonary inflammation and muscular atrophy. COPD is a heterogeneous disease encompassing inflammation and excessive mucus secretion in the large and small airway as well as destruction of the alveolar sacs. Airway remodeling occurs as a result of inflammation associated with emphysema, leading to disruption in the alveolar attachment of the small airways and subsequent airway closure during exhalation (as alveolar attachments are no longer able to hold the airway open). Disease progression leads to air trapping, hyperinflation and reduced inspiratory capacity.
  • COPD comprises chronic obstructive bronchitis (clinically defined) and emphysema (pathologically or radiologically defined), and many patients have features ofboth.
  • Chronic obstructive bronchitis is chronic bronchitis with airflow obstruction.
  • Chronic bronchitis is defined as productive cough on most days of the week for at least three months total duration in two successive years.
  • Chronic bronchitis becomes chronic obstructive bronchitis if spirometric evidence of airflow obstruction develops.
  • Chronic asthmatic bronchitis is a similar, overlapping condition characterized by chronic productive cough, wheezing, and partially reversible airflow obstruction; it occurs predominantly in smokers with a history of asthma. In some cases, the distinction between chronic obstructive bronchitis and chronic asthmatic bronchitis is unclear.
  • Emphysema is destruction of lung parenchyma leading to loss of elastic recoil and loss of alveolar septa and radial airway traction, which increases the tendency for airway collapse. Lung hyperinflation, airflow limitation, and air trapping follow. Airspaces enlarge and may eventually develop bullae.
  • bronchodilators administered via inhalation, including inhaled long-acting beta 2 -agonists (LABA) or long acting muscarinic antagonists (LAMA).
  • LAMA long acting muscarinic antagonists
  • corticosteroids have been proven effective in other inflammatory diseases such as asthma, rheumatoid arthritis, and ulcerative colitis, their use is often ineffective in COPD outside of exacerbation reduction, leading some to question their importance as a therapeutic in the disease.
  • combinations of bronchodilators with long acting corticorsteroids have found utility in preventing COPD exacerbations and treating contaminant asthma, but the utility of corticosteroids alone have not been demonstrated.
  • various double and triple combination products using corticosteroids are in development. Corticosteroid Resistance
  • Aerosols are partially blocked or blocked by collapsed airways.
  • Aerosols produced near the end of the inspiratory breath will not have sufficient time to deposit in the small airways before exhalation.
  • HDAC histone deacetylase
  • CR is also thought to occur when there is a lack of IL-10 secretion from regulatory T cells.
  • IL-10 plays an important role in the downregulation of Thl inflammatory cytokines and promotion of regulatory T cells which help to control the inflammatory response.
  • a study investigating the response of CR CD4+ T cells to calcitriol and dexamethasone it was found that co-administration of these agents to cell lines increased IL-10 levels to those seen in normal, corticosteroid-sensitive cell lines. Accordingly, recent studies support the theory that CR may be the result of physiological changes manifested at the molecular level and likely induced by pulmonary trauma such as that caused by cigarette smoking or other oxidative stress. Nevertheless, though the role of C resistance has been identified, no effective therapeutic means or strategies are available for reducing or reversing COPD-related consequences of CR resistance.
  • Vitamin D is a lipophilic small molecule responsible for maintaining normal calcium metabolism in the body. It encompasses several vitamers including vitamin Di, vitamin D 2, vitamin D 3, vitamin D 4j and vitamin D 5 .
  • Cholecalciferol (vitamin D 3 ) is the animal-derived form of vitamin D and is produced in the skin when ultraviolet radiation cleaves the steroidal ring of 7-dehydrocholestorol. In humans, the majority of cholecalciferol is maintained by sun light exposure; however, it may also be supplemented to some extent by dietary consumption.
  • calcidiol 25- hydroxyvitamin D 3
  • calcitriol 1,25-dihyroxyvitamin D 3
  • Synthetic versions of calcitriol have been produced by the pharmaceutical industry, as well as other synthetic activators of the vitamin D receptor, doxercalciferol and paricalcitol.
  • Cholecalciferol (vitamin D 3 ) Ergocalciferol (vitamin D 2 )
  • Calcitirol acts on a variety of inflammatory cells including monocytes, macrophages, dendritic cells, effector T cells, and B cells and in turn affects the expression genes encoding for chemical mediators of inflammation.
  • T H 1 associated cytokines such as IL-2, IL-6, IL-8, lL- 12. and IFNy, are generally downregulated by calcitriol and may lead to a more ⁇ ⁇ (1 mediated inflammation through the upregulation of 1L-4 ⁇ Mora et al. Nat. Rev. Immunol. 8(9) (2008) 685-698).
  • T H 2-associated pulmonary inflammation may also be reduced (as measured through a reduction in 1L-5 and eosinophils in bronchioalveolar lavage fluid), despite the apparent shift toward T H2 cytokine expression systemically ⁇ Sandhu et al. American College of Allergy, Asthma, & Immunology 105(3) 191-199). While the anti-inflammatory mechanisms behind these seemingly contradictory findings remain unclear, the upregulation of IL-10, an anti- inflammatory cytokine inhibiting T H l and T H 2 responses, could be attributed to calcitirol's broad inflammation reduction effects.
  • Calcitirol has been shown to promote IL-10 secreting regulatory T cells as well as IL-10 expression by dendritic cells in preclinical models.
  • Xystrakis et al. The Journal of Clinical Investigation 116(1) (2006) 146-155.
  • Vitamin D has been demonstrated to play an important role in improved lung function.
  • a trial in asthmatic adults with varying levels of vitamin D has shown that a 22.7 m L mean increase in FEVi can be expected for every 1 ng/m ! . increase in systemic vitamin (D Sutherland et al. Am. J. Respir. Crit. Care Med, 181(7) (2010) 699-704).
  • steroid dose used for asthma maintenance therapy was inversely proportional to systemic vitamin D levels. It was also found that vitamin D levels were directly proportional to FEVI and inversely proportional of circulating IgE concentrations (The Journal of Allergy and Clinical Immunology 125(5) (2010) 995-1000).
  • vitamin D may also function as an anti-proliferative, effective against cancer.
  • the anti-tumor effects of vitamin D are multifaceted and most likely due to the arrest of Go/ Gi phase of the cell cycle, induction of apoptosis, inhibition of cell growth, and induction of cell differentiation in malignant cells.
  • the activity of vitamin D toward a variety of cancer lines is attributed to the presence of the vitamin D receptor (VDR) in the cell membranes of these malignant cell types.
  • VDR vitamin D receptor
  • vitamin D therapy is important for osteoporosis, hypocalcemia, hyperparathyroidism and cancer. Accordingly, there exists a need for effective dosing and administration of vitamin D wherein toxic side effects are reduced and preferably eliminated.
  • dosing and administrative means should be easy to handle and safe for the user to receive the prescribed amount of vitamin D in a form that is metabolically and physiologically appropriate.
  • Vitamin A is important for lung development and lung function through generating alveolar septa which are capable of gas exchange. These effects are mediated by the Retinoic Acid Receptor [RAR] gamma subtype in alveolar walls, and are triggered by All Trans Retinoic Acid (ATRA), which is the active metabolite of Vitamin A. Exogenous ATRA can influence the formation of alveoli in newborn and adult rodents Am J Physiol: Lung Cell and Mol. Physiol 2004 286; 2: ppL249-256.
  • RAR Retinoic Acid Receptor
  • ATRA All Trans Retinoic Acid
  • ATRA treatment of adult rats with preexisting elastase-induced emphysema induces alveolus formation returning the size, number, and surface area of alveoli, and tissue elastic recoil, to values present in same-aged rats not treated with elastase (Nat Med 1997 3: pp675-677), These effects are governed by the effects of the RAR on gene expression.
  • ATRA diminishes the formation of pulmonary emphysema in mice exposed to cigarette smoke and decreases the distance between alveolar walls in mice with emphysema produced by cigarette smoke. It therefore follows that ATRA therapy, or therapy with RAR specific agents has the possibility to treat COPD, COPDe and emphysema by generating new alveoli for greater gas exchange, however no such therapies are currently available.
  • ATRA is known to induce matrix-metal loprotcinasc-9 (MMP-9) and Interleukin-8 which are likely additive to the inflammatory cascade in COPD and emphysema and cause progressive loss of pulmonary function and likely destruction of newly formed alveoli (Br J Haematol. 2002 118:2: pp419-25).
  • MMP-9 matrix-metal loprotcinasc-9
  • Interleukin-8 Interleukin-8
  • Small size particles may develop an electrostatic charge on themselves during manufacturing and storage. This may cause the particles to agglomerate or aggregate, resulting in clusters of particles which have an effective size greater than 5 microns. The probability of these large clusters navigating to the deep lungs then decreases. This in turn results in a lower percentage of the packaged drug being available to the patient for absorption.
  • the amount of active drug that needs to be delivered to the patient may be of the order of 10s of micrograms. For example, in the case of albuterol, a drug used in asthma, this is usually 25 to 100 micrograms. Current manufacturing equipment cannot effectively deliver aliquots of drugs in milligram dose range with acceptable accuracy. So the standard practice is to mix the active drug with a filler or bulking agent such as lactose. This additive also makes the drug "easy to flow”.
  • This filler is also called a carrier since the drug particles also stick to these particles through electrostatic or chemical bonds. These carrier particles are very much larger than the drug particles in size. The ability of an inhaler to separate drug from the carrier is an important performance parameter in the effectiveness of the design.
  • Prior art dry powder inhalers usually have a means for introducing the drug (active drug plus carrier) into a high velocity air stream.
  • the high velocity air stream is used as the primary mechanism for breaking up the cluster of micronized particles or separating the drug particles from the carrier.
  • inhalation devices useful for dispensing powder forms of medicament are known in the prior art. For example, in U.S. Pat. Nos. 3,507,277; 3,518,992; 3,635,219; 3,795,244; and 3,807,400, inhalation devices are disclosed having means for piercing of a capsule containing a powdered medicament, which upon inhalation is drawn out of the pierced capsule and into the user's mouth.
  • 3,831 ,606 discloses an inhalation device having multiple piercing pins, propeller means, and a self-contained power source for operating the propeller means via external manual manipulation, so that upon inhalation the propeller means aids in dispensing the powder into the stream of inhaled air. See also U.S. Pat. Nos. 3,948,264 and 5,458, 135.
  • a dry powder inhaler having a first chamber such as a blister pack or other container, for and holding a dry powder, and a second chamber connected to the first chamber via a passageway for receiving an aerosolized form of the dry powder from the first chamber and for delivering the aerosolized dry powder to a user.
  • a vibrator is coupled to the dry powder in the first chamber. The vibrator is energized and coupled to the first chamber and drives the powder from the chamber by synthetic jetting.
  • controlled aliquots or doses of a medication or drug are pre-packaged in a blister pack, which includes a frangible crowned top element which may be conical, conical with a rounded point, rounded, or other raised shape configuration, and a bottom element which may be a flat web or membrane, or which itself may be of shaped configuration, e.g. conical, round, dish shaped, etc. for closely engaging with an underlying vibrating element, the shape and size of which is chosen to provide optimum controlled delivery of a given medication or drug.
  • a frangible crowned top element which may be conical, conical with a rounded point, rounded, or other raised shape configuration
  • a bottom element which may be a flat web or membrane, or which itself may be of shaped configuration, e.g. conical, round, dish shaped, etc. for closely engaging with an underlying vibrating element, the shape and size of which is chosen to provide optimum controlled delivery of a given medication or drug.
  • the top element of the blister pack is pierced with a piercing device such as a sharp needle to form one or more apertures for delivery of the medication or drug contained within the blister pack.
  • a piercing device such as a sharp needle to form one or more apertures for delivery of the medication or drug contained within the blister pack.
  • the hole pattern and hole size is selected to provide optimization of delivery of the particular medication or drug packaged therein.
  • Metered dose inhalers have a pressurized canister filled with a liquid propellant.
  • the drug is either suspended or dissolved in the propellant.
  • the MDIs have a metering valve for metering out a known quantity of the propellant and hence the drug.
  • the propellant evaporates leaving behind a fine aerosol of the drug suitable for inhalation by the patient.
  • the patient needs to coordinate breath inhalation with the discharge of the drug from the canister. Patients are not always effective in achieving this coordination leading to dose variability.
  • the MDI is normally recommended to be used with a spacer especially for children.
  • the primary function of the spacer is to slow down the MDI discharge and function as a holding chamber for the aerosol plume.
  • a face mask may be attached to the end of the spacer.
  • Nebulizers Nebulizers, such as the jet nebulizers, produce a fine aerosol mist/droplets which carry the drug either as a suspension or dissolved in the aqueous medium.
  • the jet nebulizers use compressed air to atomize the aqueous solution.
  • the flow rate of the compressed air should be matched to the inhalation flow rate of the patient for optimum delivery of the drug.
  • a drug can be administered to a patient with repetitive non-forced inhalation over a prolonged period of time.
  • the amount of drug delivered is influenced by a large number of factors such as viscosity, volume of drug fill, surface tension, inhalation flow, etc.
  • the amount of drug delivered ranges from 3% to 6% for pediatric patients and 3% to 13% for adults.
  • Pediatric delivery nebulizers are normally coupled to a face mask.
  • nebulizer Since the nebulizer continues to produce the aerosol during the exhale cycle of the breath this leads to drug wastage, increased exposure of the drug to the patient's face and eyes and also to the caregiver.
  • the disadvantages of nebulizers in general are their poor efficiency of delivery to the patient, a requirement for a compressor or compressed air and long delivery times, on the order of 5 to 20 minutes.
  • the present disclosure provides an improvement over prior art devices such as discussed above by providing methods for treating pulmonary disease comprising the use of improved inhaler devices for the delivery of therapeutic compositions via inhalation.
  • the improved methods of the present invention satisfy the heretofore unmet need in the art for methods and devices that enable the efficient deposition of therapeutic and pharmaceutical agents to the small airways and parenchyma of the lungs.
  • the inhalers combine the properties of controlling the drug particle size as well as the dosing mechanism by which the drug is delivered to the subject.
  • the methods of the present invention are particularly useful for addressing complications associated with pulmonary disease including, but not limited to, corticosteroid resistance (CR), as the devices used herein have the functionality to deliver drugs (such as CR reversal agents) deep into the lung tissues, and may also be configured to deliver more than one therapeutic agent (i.e. CR reversal agent and corticosteroid).
  • drugs such as CR reversal agents
  • corticosteroid resistance CR
  • the devices used herein have the functionality to deliver drugs (such as CR reversal agents) deep into the lung tissues, and may also be configured to deliver more than one therapeutic agent (i.e. CR reversal agent and corticosteroid).
  • the methods and compositions of the present invention may be further utilized for addressing physiological and anatomical destruction associated with pulmonary malfunction; for example, in certain embodiments, the methods and compositions of the present invention may be targeted to improving alveolar function and development via the administration of alveolar regrowth and/or maintenance agents
  • the methods and compositions described herein are particularly suited for depositing therapeutic agents necessary for alleviating symptoms associated with pulmonary disease and malfunction, however, as would be evident to one skilled in the art, they may also be utilized for additional indications.
  • Another object of the present invention is to provide improved methods and devices for the delivery of therapeutic and pharmaceutical agents to the small airways and parenchyma of the lungs, wherein such devices combine controlling drug particle size and delivery mechanism to optimize delivery.
  • Another object of the present invention is to provide improved methods and devices for the delivery of therapeutic and pharmaceutical agents to the small airways and parenchyma of the lungs, wherein such devices are self-contained, easy to use, and improve therapeutic compliance.
  • a further object of the present invention is to provide improved methods and devices for the delivery of therapeutic and pharmaceutical agents to the small airways and parenchyma of the lungs, wherein the therapeutic and pharmaceutical agents alleviate and prevent symptoms associated with asthma, atelectasis, bronchitis, COPD, emphysema, lung cancer, pneumonia and pulmonary edema.
  • Another object of the present invention is to provide improved methods and devices for the delivery of therapeutic and pharmaceutical agents to the small airways and parenchyma of the lungs, wherein the therapeutic and pharmaceutical agents alleviate and prevent symptoms associated with corticosteroid resistance (CR).
  • CR corticosteroid resistance
  • Another object of the present invention is to provide improved methods and devices for the delivery of therapeutic and pharmaceutical agents to the small airways and parenchyma of the lungs, wherein the therapeutic and pharmaceutical agents improve the development and regrowth of lung tissue.
  • a further object of the present invention is to provide improved methods and devices for the delivery of therapeutic and pharmaceutical agents to the small airways and parenchyma of the lungs, wherein the therapeutic and pharmaceutical agents improve the development, and regrowth of alveoli, and subsequent maintenance of the regrown alveoli.
  • Yet another object of the present invention is to provide improved methods and devices for the delivery of therapeutic and pharmaceutical agents to the small airways and parenchyma of the lungs, wherein the devices may be configured to deliver more than one therapeutic or pharmaceutical agent.
  • a further object of the present invention is to provide improved methods and devices for the delivery of therapeutic and pharmaceutical agents to the small airways and parenchyma of the lungs, wherein the devices may be configured to deliver more than one therapeutic or pharmaceutical agent such as those comprising, but not limited to, CR reversal agents, corticosteroids, bronchodilators, vitamin D (and active metabolites, vitamin D receptor agonists/partial agonists and equivalents thereof), and vitamin A (and active metabolites, vitamin A receptor agonists/partial agonists and equivalents thereof).
  • Another object of the present invention is to provide improved methods and devices for the delivery of therapeutic and pharmaceutical agents, which are targeted to be delivered to the small airways and parenchyma of the lungs, wherein the therapeutic and pharmaceutical agents comprise corticosteroids, muscarinic antagonists, macrolides, non-steroidal anti -inflammatory drugs (NSAIDs), branch odilators and CR reversal agents.
  • the therapeutic and pharmaceutical agents comprise corticosteroids, muscarinic antagonists, macrolides, non-steroidal anti -inflammatory drugs (NSAIDs), branch odilators and CR reversal agents.
  • Another object of the present invention is to provide improved methods and devices for the delivery of therapeutic and pharmaceutical agents to the small airways and parenchyma of the lungs, wherein the CR reversal agents comprise antioxidants, iNOS inhibitors, Phosphoinositide-3-kinase-6 inhibitors, p38 MAP kinase inhibitors, JNK inhibitors, MIF inhibitors, p-glycoprotein inhibitors, macrolides, calcineurin inhibitors, and vitamin D, synthetic vitamin D, vitamin D analogs, calcitiol and equivalents thereof.
  • the CR reversal agents comprise antioxidants, iNOS inhibitors, Phosphoinositide-3-kinase-6 inhibitors, p38 MAP kinase inhibitors, JNK inhibitors, MIF inhibitors, p-glycoprotein inhibitors, macrolides, calcineurin inhibitors, and vitamin D, synthetic vitamin D, vitamin D analogs, calcitiol and equivalents thereof.
  • Another object of the present invention is to provide improved methods and devices for the delivery of therapeutic and pharmaceutical agents to the small airways and parenchyma of the lungs, wherein the agents for improving pulmonary tissue growth and development comprise vitamin A, All Trans Retinoic Acid (ATRA), retinoic acid receptor (RAR) agonists and RAR selective alveolar growth agents and equivalents thereof.
  • agents for improving pulmonary tissue growth and development comprise vitamin A, All Trans Retinoic Acid (ATRA), retinoic acid receptor (RAR) agonists and RAR selective alveolar growth agents and equivalents thereof.
  • Another object of the present invention is to provide improved methods and devices for the delivery of therapeutic and pharmaceutical agents to the small airways and parenchyma of the lungs, wherein the therapeutic and pharmaceutical agents comprise CR. reversal agents and corticosteroids.
  • Another object of the present invention is to provide improved methods and devices for the delivery of therapeutic and pharmaceutical agents to the small airways and parenchyma of the lungs, wherein the therapeutic and pharmaceutical agents comprise budesonide, fluticasone, beclomethasone, flunisolide, triamcinolone, mometasone, any derivative or pharmaceutically acceptable salt thereof, or any other corticosteroid suitable for inhalation such as prodrugs (i.e. ciclesonide) or "soft" steroids which offer milder immunosuppression and fewer steroid side effects (i.e. loteprednol, fluorometholone).
  • the therapeutic and pharmaceutical agents comprise budesonide, fluticasone, beclomethasone, flunisolide, triamcinolone, mometasone, any derivative or pharmaceutically acceptable salt thereof, or any other corticosteroid suitable for inhalation such as prodrugs (i.e. ciclesonide) or "soft" steroids which offer milder immunosuppression and
  • Another object of the present invention is to provide improved methods and devices for the deliver ⁇ ' of therapeutic and pharmaceutical agents to the small airways and parenchyma of the lungs, wherein the therapeutic and pharmaceutical agents comprise a combination of therapeutic agents selected from the group consisting of bronchodilators, CR reversal agent, a corticosteroid and pulmonary tissue growth and development agents such as vitamin A.
  • Another object of the present invention is to provide improved methods and devices for the delivery of therapeutic and pharmaceutical agents to the small airways and parenchyma of the lungs, wherein the therapeutic and pharmaceutical agents comprise calcitriol, fluticasone and a bronchodilator.
  • a further object of the present invention is to provide improved methods and devices for the delivery of therapeutic and pharmaceutical agents to the small airways and parenchyma of the lungs, wherein the therapeutic and pharmaceutical agents alleviate and prevent symptoms associated with non-pulmonary diseases and malfunctions.
  • Figure 1 provides a schematic summarizing the experimental design of the effect of treatment of therapeutic compositions as described in Example 7 on smoke-exposed female mice.
  • the methods and compositions of the present invention are particularly suited for the delivery of therapeutic and pharmaceutical agents to the lung. More specifically the methods and compositions of the present invention are particularly suited for the delivery of therapeutic and pharmaceutical agents to all the airway passages within the lung, including but not limited to, the bronchioles, the respiratory bronchioles, the alveolar ducts, the atria, the alveolar sacs, the alveoli (air sacs or clusters of cells).
  • the present invention is further suited for the delivery of therapeutic and pharmaceutical agents to the circulatory system of the lung, including but not limited to, the pulmonary artery, pulmonary capillaries, pulmonary veins, bronchial arteries, and bronchial veins.
  • the unique features of the present invention enable the user of the inhaler to receive an effective dose of the desired pharmaceutical or therapeutic agent in an optimal manner.
  • the inhalers used herein enable site-specific delivery of micronized dry powder or liquid medicaments in optimal fashion as a result of novel mechanical features that combine the dynamic properties of flow and inspiration, such that the user receives an appropriate therapeutic amount of the medicament.
  • the present invention satisfies the long felt need in the market for a device that has the capability to deliver medicaments in micronized form.
  • the invention enables the delivery of medicaments having a particle size that is sufficiently small per mass median aerodynamic diameter (MMAD), and has the appropriate geometric standard deviation (GSD) to effectively target the airways of the lung, in particular the small airways of the lung.
  • MMAD per mass median aerodynamic diameter
  • GSD geometric standard deviation
  • the internal mechanical features as described above enable the use of the device even by flow-restricted subjects for whom minimal flow rates are often problematic.
  • the combination of features with the ergonomic design of the inhaler result in an easy to use device which is necessary for subjects having limited or restricted physical abilities (such as the elderly, very young, or infirm).
  • the methods taught herein are directed to the treatment of pulmonary disease.
  • pulmonary diseases such as asthma, atelectasis, bronchitis, COPD, emphysema, lung cancer, pneumonia and pulmonary edema.
  • CR corticoidsteroid resistance
  • HDAC2 histone deacetylase 2
  • IL-10 is known to play an important role in the downregulation of Thl inflammatory cytokines and the promotion of regulatory T cells which help to control the inflammatory response. Certain studies have demonstrated that increasing IL- 10 levels to normal levels, alleviates some of the problems associated with CR resistance.
  • the methods and devices of the present invention overcome problems associated with prior art methods such as those that result in undesirable side effects including diminished drug responsiveness due to non-targeted methods drug administration.
  • the novel features of the present invention enable controlled site delivery, namely the deposition of CR reversal agents in proximity to, or at the location of, corticosteroid deposition.
  • the present invention addresses the complications that may arise from delivering more than one therapeutic agent wherein each agent displays dissimilar aerosol characteristics and deposition patterns.
  • the invention satisfies the need for delivery of corticosteroids and agents for reversal of CR to the lungs where heightened local concentrations are obtained, systemic levels are minimized, and synergistic immunomodulating aspects of the two moieties are realized.
  • the present invention provides novel methods and devices for pulmonary delivery of corticosteroids with agents for reversal of CR to a mammalian host, particularly a human patient, whereby a more significant and/or prolonged immunomodulatory response greater than that achieved by the corticosteroid alone is achieved.
  • pulmonary co-administration of a corticosteroid with an agent for reversal of CR allows for lower dosage levels than would be necessary to achieve a similar pulmonary therapeutic response by other methods of delivery (i.e. oral delivery, intravenous delivery). This allows for reduction of systemic side effects of either or both agents.
  • co-administration allows direct targeting of the agent for reversal of CR to the site of action, since aerosol deposition of both agents occurs at the same region of the lung and throughout the lung compartments.
  • Precise targeting of CR reversal agents allows for high local concentrations in the region of corticosteroid deposition, creating a microenvironment where corticosteroid activity is increased.
  • Co-administration as described above offers a more patient compliant alternative to multiple-dosage medicaments and also provides greater therapeutic efficacy by supplying therapeutic levels of drug at the same tissue targets (particularly important for CR reversal).
  • the unique features of this invention resulting in the direct administration of CR reversal agents to the lungs, enhance overall therapeutic effectiveness.
  • targeted drug delivery according to the methods herein result in advantages including, but not limited to, prolonged release resulting from slow dissolution, preferential lung tissue residence resulting from lipophilic interactions/cellular retention mechanisms, enhancement of pulmonary bioavailability resulting from avoidance of intestinal and hepatic metabolism, and enhancement of pulmonary bioavailability resulting from avoidance of poor absorption through the gastrointestinal wall.
  • the CR reversal agent comprises vitamin D, vitamin D analogs, synthetic vitamin D, vitamin D receptor agonists and antagonists, calcitriol, calcitol and equivalents thereof.
  • CR reversal agents known to those skilled in the art, including, but not limited to, antioxidants, iNOS inhibitors, Phosphoinositide-3-kinase-5 inhibitors, theophylline, p38 MAP kinase inhibitors, JNK inhibitors, MIF inhibitors, p-glycoprotein inhibitors, macrolides, and calcineurin inhibitors.
  • vitamin D is intended to encompass not only vitamin D2 and vitamin D3, but any salt, metabolite, or derivative of vitamin D having immunoregulatory activity like vitamin D, and which is non-toxic and pharmacologically acceptable, for example, calcitriol.
  • One embodiment of the present invention comprises the administration of dry powder calcitriol via inhalation.
  • Dosing ranges for such therapeutic administration may range from 0.0025 ⁇ g to 10 ⁇ g, from 0.05 ⁇ g to 5 ⁇ g, or from O. ⁇ g to 2 ⁇ g.
  • the mass median particle size of the calcitriol dry powder may range from 0.1 ⁇ to 10 ⁇ , from 0.25 ⁇ to 5 ⁇ , or from 0.5 ⁇ to 4 ⁇ .
  • appropriate dosing levels are ultimately determined by the size, weight, and age of the patient, as well as severity of symptoms to be treated. Nevertheless, one unique aspect of the present invention comprises low effective dosaging ranges.
  • the unique methodology of the present invention enables the patients with pulmonary problems to receive compositions comprising vitamin D, including calcitriol, in low but highly effective doses.
  • High vitamin D dosing levels can cause toxicity, however the effective delivery of low dosages of enables the patient to receive the beneficial effects of the therapeutic composition without potential toxicity.
  • delivery of vitamin D compositions via inhalation has been discussed, but not actually reduced to practice.
  • the inventors of the present invention have overcome problems such as toxicity and inability to achieve an effective concentration at the site of action, by developing stable, consistent dry powder formulations and effectively delivering them to the target lung region even for patients with compromised pulmonary function. Accordingly, though prior art studies and discussions make reference to vitamin D inhalation, successful therapeutic intervention comprising vitamin D inhalation was not accomplished until the present inventors demonstrated the delivery of vitamin D dry powder compositions by coupling suitable formulations with delivery via inhalation.
  • calcitriol As referenced earlier, therapeutic effects of calcitriol have been documented in scientific studies for both pulmonary disease and for cancer. However, in such studies, calcitriol is utilized in very high doses in order for a positive effect to be attained. High dosing of calcitriol poses significant problems associated with toxicity due to hypercalcemia. Nevertheless calcitriol has the potential to function as an important and effective anti-inflammatory pharmaceutical, especially in the area of pulmonary disease such as COPD where there is no currently available effective anti-inflammatory therapeutic.
  • the present invention overcomes prior art problems by providing novel methods and compositions of calcitriol that are suitable for achieving therapeutic concentrations in the lung following low dose delivery via inhalation as opposed to oral intake which requires very extremely high doses to achieve the same lung concentrations and therefore risk significant toxicity.
  • the methods and compositions of the present invention satisfy the long felt need in the art for a pulmonary disease therapeutic that not only results in the reduction inflammation and corticosteroid resistance, but also significantly minimizes toxicity.
  • dry powder calcitriol comprises a crystalline anhydrous form that is micronized to a particle size less than volume median particle size of approximately 2-8 microns and most preferably approximately 1 -4 microns and is formulated with anhydrous lactose.
  • calcitriol may be prepared into a liquid calcitriol/lactose feedstock and processed using spray drying and/or ultrasonic evaporation processes to yield calcitriol-lactose fused crystals with a particle size less than volume median particle size of approximately 5 microns at a ratio of 1 : 10-1 : 1000, such fused crystals may be further formulated with anhydrous carrier lactose.
  • the formulations of calcitriol contain no triazoline adduct of pre-calcitriol and methylene calcitriol.
  • the dry powder calcitriol compositions as described above may be administered to patients via the use of an inhalation device.
  • such calcitriol compositions are administered using proprietary technology developed by MicroDose Therapeutx, Inc. (Monmouth Junction, New Jersey).
  • the compositions are packaged for unit dose delivery of 0.25-10.0 micrograms, 0.5-5.0 micrograms or 0.1-2.5 micrograms (or varying ranges thereof) in a dry powder inhaler (DPI) available from MicroDose Therapeutx, Inc.
  • DPI dry powder inhaler
  • calcitriol compositions described herein via the inhalers developed by MicroDose Therapeutx, Inc. (as described in United States Patent Application Serial Nos. 12/785,082, 12/828,133 and 12/985,158) accomplishes successful administration of appropriate doses to desired sites within the lung and pulmonary tissue. More specificially, calcitriol compositions may be delivered to small airways and parenchyma of the lungs for optimal results, namely reduction in corticosteroid resistance. Patients having compromised lung function benefit from the methods described herein as administration of therapeutic compositions are accomplished at a low flow rate.
  • Patients having a breathing flow rate of even a minimal 10 L/min may utilize the inhalers described herein and dosing may be accomplished via tidal breathing irrespective of any specifically required breathing pattern.
  • the inhaler is designed to deliver drug in a single breathing maneuver at flow rates up to 30 L/min or over a series of tidal inhalations at peak flow rates less than 25 L/min.
  • the administration of calcitriol may be optionally coupled with a pulmonary tissue growth or repair agent to take advantage of the anti- inflammatory action of calcitriol in offsetting selective pro-inflammatory action of the pulmonary tissue growth or repair agent.
  • the administration of the calcitriol compositions as described above may be preceded by the administration of bronchodilator.
  • therapeutic intervention may involve the preliminary administration of a bronchodilator, followed by the administration of calcitriol optionally combined with a steroid such as fluticasone.
  • the therapeutic regimen recommends implementation of the methods described herein at specific times of the day in order to optimize effectiveness based on natural biological variation in calcitriol metabolism. For example, since calcitriol exhibits diurnal variation with the low at around 0400 hr and a peak at 1600 hr followed by a decline in the evening, in a preferred embodiment, calcitriol dosing is recommended at night (preferably between 1800hr and 2000hr) to maximize local supplementation of calcitriol.
  • vitamin A therapeutic compositions are delivered in close proximity to damaged alveoli for direct effect. More specifically, the delivery methods of the present invention achieve optimal delivery of vitamin A compositions at low doses thereby reducing unnecessary side effects such as skin reactions (for instance, mucucutaneous eruptions), and headache.
  • the unique aspects of vitamin A composition delivery as claimed herein comprise stable formulations and delivery systems optimized to administer less than 500 ⁇ g of active vitamin A compositions to patients with compromised lung function; such delivery systems coincide with tidal breathing and unlike currently available commercial devices, do not require coordination with a predetermined breathing patterns by a patient.
  • One embodiment of the present invention comprises the administration of dry powder vitamin A compositions via inhalation. Dosing ranges for such therapeutic administration may range from 0.05 ⁇ g to 10 ⁇ g, from 0.1 ⁇ g to 5 ⁇ g, or from 1 ⁇ g to 4 ⁇ g. In addition, the mass median particle size of the vitamin A dry powder may range from 1 053513
  • one unique aspect of the present invention comprises low effective dosing ranges.
  • the unique methodology of the present invention enables the patients with pulmonary problems to receive compositions comprising vitamin A, including ATRA, in low but highly effective doses.
  • the vitamin A compositions of the present invention include 'alveolar growth agents' that promote the generation of new alveoli and are selected from agents that interact with the Retinoic Acid Receptor (RAR). Also included are 'alveolar maintenance' agents used in combination to maintain newly generated alveoli from being attacked by the progressive nature of COPD and to minimize unexpected deleterious effects of the aforementioned RAR therapy.
  • RAR Retinoic Acid Receptor
  • alveolar growth agents have been considered in clinical studies, however all such studies have been limited to methods of administration that do not include inhalation. These agents include but are not limited to ATRA, ATRA derivatives, RAR agonists, 13-cis Retinoic acid and RAR selective agonists i.e. palovarotene.
  • the methods of the present invention comprise compositions for inhalation with the goal of maximizing drug concentrations in the target (lung) and minimizing systemic exposure to the rest of the body.
  • the present invention further comprises alveolar maintenance agents including but not limited to: macrolides (Cyclosporine, Tacrolimus, Sirolimus, Clarithromycin, erythromycin, telithromycin, azithromycin), immunosuppressants (Mycophenolate sodium), anti-ma!arials (Hydroxychloroquine, mefloquine), NSAIDS (fenspiride), anti- oxidants (quercetin, curcumin compounds) and other vitamins/vitamin derivatives (vitamin D, C, E).
  • the novel methods and compositions of the present invention comprise vitamin A formulations for inhalation which serve to minimize systemic exposure, provide effective amounts of both agents to the target organ (the lung) and avoid the complex systemic metabolism and bioavailability issues of ATRA and RAR agents.
  • compositions of the present invention overcome current problems in the prior art by achieving the effective delivery of therapeutic compositions via inhalation for alleviating and reducing symptoms associated with pulmonary disease.
  • the compositions of the present invention comprise agents for reversing corticosteroid resistance such as vitamin D, calcitriol and equivalents thereof.
  • the compositions of the present invention comprise alveolar growth and maintenance agents such as ATRA and erythromycin.
  • the present invention may comprise a combination of therapeutics: certain embodiments may comprise agents for reversing corticosteroid resistance as well as agents for alveolar regrowth. Certain other embodiments may further comprise an alveolar maintenance agent. Additional embodiments may optionally comprise bronchodilating substances.
  • Certain preferred embodiments of the present invention comprise methods for the treatment of pulmonary disease comprising the administration of compositions comprising vitamin D and vitamin A via inhalation. More specifically, certain preferred embodiments comprise methods for the treatment of pulmonary disease, such as COPD, comprising the administration of compositions comprising calcitriol and ATRA via inhalation. Such embodiments overcome prior art problems associated with toxicity and achieve optimal therapeutic effect as a result of controlled site delivery.
  • certain preferred embodiments comprise methods of delivering calcitriol and ATRA in ratios from 1 :50 to 1 :500000 and more preferably from 1 :500 to 1 :50000. Also, plasma levels of calcitriol do not exceed 30 pg/mL above baseline levels in serum 4 hours following administration. Inhalers
  • the inhalers of the present invention have the unique ability to deliver micronized medicaments to the lung airways, and more particularly to the small lung airways such that uptake of the medicament is accelerated and optimized.
  • the specific embodiments and details of inhalers contemplated for use herein are described in detail in United States Patent Application 12,785,082 (Unites States Published Application No. 20100294287) filed on May 21, 2010, United States Patent Application 12,828,133 (Unites States Published Application No. 20110000481) filed on June 1 , 2010 and United States Patent Application 12,985, 158 (Unites States Published Application No.
  • the methods of the present invention comprise devices wherein the improvements pertain to the internal dosing mechanics of the devices, the administration of individual doses, and also to the general delivery of the medicament.
  • one improvement pertains to the embodiment of an inhaler having a vibration element for aerosolizing medicament contained in a blister pack, wherein the inhaler is adapted to hold a plurality of individual blister packs which can be individually accessed and moved into an operative or dispensing position between the vibration element and a piercing element.
  • the advantages of this construction include: simpler, more compact assembly for an inhaler containing a plurality of blister packs; and the ability to isolate and shield individual blister packs from the piercing element prior to use.
  • An additional improvement pertains to an inhaler comprising a compact size pharmaceutical delivery package including a unique dose drum formed into a cylinder and containing a plurality of dose compartments for containing individual doses. This improvement results in better therapeutic compliance by ensuring that the appropriate dose is delivered to a patient.
  • nebulizer that is particularly useful for pediatric patients and other patients with compromised physical abilities.
  • the nebulizer contemplated herein utilizes a powder plume, that enables the delivery of aerosolized dry powders in much higher dose concentrations than are possible with liquid carried drugs.
  • the generation of powder plume is independent of inhalation rate and inhalation timing and the use of the nebulizer results in reproducible and recordable pulmonary doses from pre-measured blister packs.
  • the inhaler of the present invention results in improved delivery of therapeutic or pharmaceutical agents by active device aerosol generation.
  • the mechanism of delivery further utilizes pulmonary fluid as a delivery medium in order to deliver "through" airflow limited airways and delivery is accomplished while maintaining positive pressure within the lung.
  • pulmonary fluid as a delivery medium in order to deliver "through" airflow limited airways and delivery is accomplished while maintaining positive pressure within the lung.
  • an additional advantage of the present invention the ability to deliver more than one therapeutic agent via inhalation without complications arising from disparate aerosolization profiles.
  • the present inhalers overcome problems that result from dissimilar aerosol characteristics and deposition patterns. Accordingly, the present invention enables the delivery of more than one therapeutic agent, i.e. CR reversal agent, corticosteroid, pulmonary/alveolar growth agent, bronchodilator.
  • the option of administering a bronchodilating substance prior to the delivery of the therapeutic agent intended for deep lung delivery is provided.
  • the bronchodilating substance may be delivered via the same inhaler device thereby increasing the subject's convenience, and ultimately improving therapeutic compliance.
  • the methods and device of the present invention are particularly desirable because a concentrated plume of drug is delivered within the small volume of inhaled air at the onset of inspiration.
  • fine drug particles mean particles having a size sufficiently small so as to be delivered to the airways of the lungs, and especially to the small airways.
  • the dry powder form of the therapeutic agents described herein preferably should be micronized, spray dried, or engineered to a maximum aerodynamic particle size in the range of 0.1 ⁇ to 10 ⁇ , from 0.25 ⁇ to 5 ⁇ , or from 0.5 ⁇ to 4 ⁇ .
  • agent for reversal of CR is intended to encompass any agent that when administered at an effective level will increase the anti- inflammatory response induced by a corticosteroid. This term applies not only agents for reversal of CR, but any salt or derivative of said agent having activity to reverse CR, and which is non-toxic and pharmacologically acceptable.
  • CR reversal agents include but are not limited to, vitamin D, vitamin D analogs, synthetic vitamin D, vitamin D receptor agonists and antagonists, calcitol and equivalents thereof. Also included are CR reversal agents known to those skilled in the art. Including, but not limited to, antioxidants, INOS inhibitors, Phosphoinositide-3-kinase-5 inhibitors, theophylline, p38 MAP kinase inhibitors, JNK 1 053513
  • MIF inhibitors MIF inhibitors
  • p-glycoprotein inhibitors p-glycoprotein inhibitors
  • macrolides calcineurin inhibitors.
  • vitamin D is intended to encompass vitamin D, vitamin D2, vitamin D3, vitamin D analogs, synthetic vitamin D, vitamin D receptor agonists and antagonists, calcitriol, calcitol and equivalents thereof
  • vitamin A is intended to encompass those agents that interact with Retinoic Acid Receptor (RAR) including but not limited ATRA, ATRA derivatives, RAR agonists, 13-cis Retinoic acid and RAR selective agonists for example, palovarotene.
  • RAR Retinoic Acid Receptor
  • alveolar growth agent is intended to encompass any agent that promotes the growth of new alveoli via the retinoic acid receptor, and includes ATRA or RAR selective agent therapy.
  • alveolar maintenance agent is intended to encompass any agent that when administered at an effective level will increase the anti- inflammatory response induced by COPD, COPDe and Emphysema and any undesirable effects of ATRA or RAR selective agent therapy. This term applies not only agents for alveolar maintenance, but any salt, hydrate, prodrug or derivative of said agent having similar activity, and which is non-toxic and pharmacologically acceptable.
  • bronchodilating substances include, but are not limited to, beta2- agonists (short and long acting, LABA), long acting muscarinic antagonists (LAMA), anticholinergics (short acting), and theophylline (long acting).
  • “Co-administered,” as used herein, means to deliver more than one pharmaceutical or therapeutic agent, for example, both corticosteroid and agent for reversal of CR as an aerosol within the same breath via the pulmonary route.
  • An effective amount is an amount of the pharmaceutical composition that is effective for achieving a desired therapeutic effect, including but not limited to bronchodilation, CR reversal, anti-inflammation, alveolar regrowth.
  • a desired therapeutic effect including but not limited to bronchodilation, CR reversal, anti-inflammation, alveolar regrowth.
  • an effective amount of an agent for reversal of CR may comprise the specified amount of calcitriol, within a defined aerodynamic particle size range suitable for absorption in the lungs, that is able to reduce or eliminate the resistance to corticosteroids.
  • pharmaceutical and therapeutic agents include but are not limited to any and all medicaments and pharmaceutical agents and formulations that may be administered for the treatment of pulmonary disease, including agents for preventing disease and including agents for maintaining improvement of disease condition.
  • therapeutic and pharmaceutical agents include, but are not limited to, corticosteroids, muscarinic antagonists, macrolides.
  • non-steroidal anti-inflammatory drugs antioxidants, iNOS inhibitors, phosphoinositide-3-kinase-5 inhibitors, p38 MAP kinase inhibitors, JNK inhibitors, MIF inhibitors, p-glycoprotein inhibitors, macrolides, calcineurin inhibitors, and vitamin D, synthetic vitamin D, vitamin D analogs, calcitiol, vitamin A, All Trans Retinoic Acid (ATRA), retinoic acid receptor (RAR) agonists, RAR selective alveolar growth agents, budesonide, fluticasone, beclomethasone, flunisolide, triamcinolone, mometasone, ciclesonide, loteprednol, fluorometholone as well as any derivative, equivalent or pharmaceutically acceptable salt thereof .
  • ATRA All Trans Retinoic Acid
  • RAR retinoic acid receptor
  • a “pharmaceutical” or “therapeutic” composition as used herein means a medicament for use in treating a patient, for example, an agent for reversal of CR in a dry powder form of a defined aerodynamic particle size prepared in a manner that is suitable for pulmonary administration to a patient.
  • a pharmaceutical composition according to the invention may optionally, include a non-toxic pharmaceutically acceptable carrier.
  • "pharmaceutical” or “therapeutic” composition may comprise a singular entity (i.e. calcitriol alone), or a combination of compositions selected from the group consisting of CR reversal agents, anti- inflammatory agents, bronchodilators, alveolar growth agents, and others.
  • agents that may be delivered via the methods and inhaler described herein include, but are not limited to chemotherapeutics, angiogenesis inhibitors, kinase inhibitors, histone deacety!ase inhibitors as we!! as other modifiers of epigenetic phenomena and proteosome inhibitors.
  • Minnetonka, MN epirubicin
  • Epoetin alfa estramustine
  • etoposide phosphate etoposide VP- 16, exemestane
  • Filgrastim floxuridine
  • fludarabine fluorouraci!
  • fulvestrant gemcitabine
  • bemtuzumab ozogamicin goserelin acetate, hydroxyurea
  • Ibritumomab Tiuxetan idarubicin, ifosfamide, imatinib mesylate, Interferon alfa-2a, Interferon alfa-2b, irinotecan, letrozole, leucovorin, levamisole, lomustine CCNU, meclorethamine (nitrogen mustard), megestrol acetate, melphalan (L-PAM), mercaptopurine (6-MP), mesna, methotrexate, methoxsalen, mitomycin C
  • Example 1 The following specific examples will illustrate the invention as it applies to the methods of treatment using the inhaler. It will be appreciated that other examples, including minor variations in procedures will be apparent to those skilled in the art, and that the invention is not limited to these specific illustrated examples.
  • Example 1
  • Inhaled corticosteroids mometasone furoate or fluticasone furoate are prepared with volume median particle size of less than 5 microns.
  • Calcitriol (1, 25- Dihydroxycholecalciferol) is also prepared in crystalline form and subsequently micronized to a volume median particle size of less than 5 microns.
  • the ICS's are incorporated at appropriately 30-50% of the commercial ICS dose when administered via a passive dry powder inhaler, due to the efficiency of the invention delivered by a dry powder inhaler (DPI) available from MicroDose Therapeutx, Inc.
  • DPI dry powder inhaler
  • One preferred embodiment utilizes an ICS dosed once daily, i.e.
  • mometasone furoate or fluticasone furoate to coincide with a once daily dose of the vitamin D receptor agonist.
  • This combination product is designed to reverse corticoidsteroid resistance (CR) by adding the protective anti-inflammatory effects of calcitriol with the local anti-inflamatory effects of these ICS's.
  • the inhaler is operated at 15 L/min and for both medicaments, the aerosol performance with a fine particle fraction (% of particles exiting the inhaler that are less than 5.8 microns) is less than or equal to_45% with at least 10% of particles in the less than 2.1 micron size range when tested with a next generation Impactor.
  • the ICS of Example 1 in crystalline form, are micronized to a maximum particle size of about 5 microns.
  • a dry powder unit dose containing clinically effective doses of either ICS is blended with 1000 micrograms lecithin and packaged for delivery in a dry powder inhaler (DPI) available from MicroDose Therapeutx, Inc. This combination is designed to spread into alveolar fluid and treat lung parenchyma through partially occluded small airways.
  • DPI dry powder inhaler
  • Example 1 or 2 Controlled Site Delivery of Corticosteroid and Corticosteroid Resistant Agents via Inhalation
  • the ICS formulation from Example 1 or 2 is combined with albuterol sulfate in crystalline form separately micronized to a maximum particle size of about 5 microns. Delivery from a multiple dose dry powder inhaler (DPI) available from MicroDose Therapeutx, Inc. (Monmouth, New Jersey) leverages the short acting bronchodilation of albuterol to allow deeper penetration of the ICS into the lung parenchyma.
  • DPI dry powder inhaler
  • Example 4 Calcitriol Compositions for Inhalation
  • Calcitriol is a synthetic vitamin D analog and has been used as a pharmaceutical as well as a nutraceutical. It is the synthetic version of a vitamin D metabolite that naturally occurs in the body. Calcitriol in the crystalline anhydrous form is micronized to a particle size less than volume median particle size of 4 microns and is formulated with anhydrous lactose. The resulting formulation has a residual moisture of less than 1 % and loss of drying of less than 1.5%. The powder is packaged for unit dose delivery of 0.5-2.5 micrograms in a dry powder inhaler (DPI) available from MicroDose Therapeutx, Inc. (Monmouth, New Jersey). The formulation is contained within a blister packaged under inert gas blanket (e.g.
  • DPI dry powder inhaler
  • Nitrogen within an aluminum -polymer laminate heat sealed blister to protect the formulation from moisture, light and oxygen.
  • the inhaler is operated at 15 L/min and yields an aerosol performance with a fine particle fraction (% of particles exiting the inhaler that are less than 5.8 microns) of at least 50% with at least 10% of particles in the less than 2.1 micron size range when tested with a next generation Impactor.
  • the formulation of calcitriol contains no triazoline adduct of pre-calcitriol and methylene calcitriol.
  • Calcitriol-Lactose Compositions for Inhalation Calcitriol is prepared into a liquid calcitriol/lactose feedstock and processed using spray drying and/or ultrasonic evaporation processes to yield calcitriol-lactose fused crystals with a particle size less than volume median particle size of 5 microns at a ratio of 1 : 10-1 : 1 : 1000.
  • the aforementioned fused crystals can be further formulated with anhydrous carrier lactose.
  • the resulting formulation has a residual moisture of less than 1 % and loss of drying of less than 1.5%.
  • the powder is packaged for unit dose delivery of 0.5-2.5 micrograms in a dry powder inhaler (DPI) available from MicroDose Therapeutx, Inc. (Monmouth, New Jersey).
  • DPI dry powder inhaler
  • ATRA and Calcitriol Compositions for Inhalation All Trans Retinoic Acid (ATRA) is prepared in crystalline form and subsequently micronized to a volume median particle size of less than 5 microns.
  • Calcitriol (1, 25- Dihydroxycholecalciferol) is also prepared in crystalline form and subsequently micronized to a volume median particle size of less than 5 microns.
  • the powder is packaged for unit dose delivery of 10-1000 micrograms of ATRA and 0.5-2.5 micrograms of calcitriol, formulated in an inhalation-grade anhydrous lactose blend in a dry powder inhaler (DPI) available from MicroDose Therapeutx, Inc.
  • DPI dry powder inhaler
  • the inhaler is operated at 15 L/min and for both medicaments, the aerosol performance with a fine particle fraction (% of particles exiting the inhaler that are less than 5.8 microns) is less than or equal to 45% with at least 10% of particles in the less than 2.1 micron size range when tested with a next generation impactor.
  • Test Articles will begin the 1 st day of CS exposure (see Figure 1) and will be administered q.d. (immediately before CS exposure) for days 1 - 5, 8 - 12, and 15 - 18. Some animals may be stagger-started as necessary to accommodate dosing, necropsy and sample processing.
  • mice will be euthanized and blood collected for blood gas analysis and plasma isolation.
  • Bronchoalveolar lavage (BAL) will be performed on the lungs using three aliquots of PBS.
  • BAL fluid will be analyzed at LRRI for total cell counts and differentials (macrophages, neutrophils, lymphocytes and eosinophils will be counted on cell differential slides).
  • Lung lobes (lavaged) and cell-free BAL supernatant will be snap-frozen and stored at -80°C.
  • Lung tissue (lavaged) will be analyzed at LRRI for IL-6, IL-10, ILl - , ILl - ⁇ , eotaxin, RANTES, MCP-1 , ⁇ - ⁇ , T F-a. KC, IL-13, GM-CSF, IP- 10, and IFN- ⁇ using Luminex. Lung tissue will also be analyzed for 11DAC2. Plasma and cell-free BAL supernatant will be stored at -80°C and sent to the sponsor.
  • cytokines cytokines, chemokines and HDAC2.
  • Plasma sent to sponsor.
  • Test Article F 8 + - ATRA (5 days/week) supernatant collected and sent to sponsor.

Abstract

La présente invention concerne des procédés et des compositions pour le traitement d'une maladie pulmonaire en utilisant l'inhalation. En particulier, la présente description concerne de nouveaux procédés et compositions pour traiter des maladies pulmonaires telles que l'asthme, la bronchite, la BPCO, l'emphysème, le cancer du poumon, la pneumonie et l'œdème pulmonaire. De plus, la présente description concerne de nouveaux procédés et compositions pour traiter des complications associées à une maladie pulmonaire telle que la résistance aux corticostéroïdes et la destruction de tissu pulmonaire. Les compositions de la présente description comprennent des agents de résistance aux corticostéroïdes comprenant mais non limitées à la vitamine D, le calcitriol et des équivalents de ceux-ci. Les compositions de la présente description comprennent en outre des agents de développement et de maintenance alvéolaire comprenant, mais non limités à, la vitamine A, ATRA et des équivalents de ceux-ci. La présente invention concerne l'administration efficace d'agents thérapeutiques à des voies respiratoires spécifiques des poumons en utilisant l'administration à un site contrôlé.
PCT/US2011/053513 2010-09-27 2011-09-27 Procédés et compositions pour le traitement de maladie en utilisant l'inhalation WO2012047674A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP11831316.2A EP2621588A4 (fr) 2010-09-27 2011-09-27 Procédés et compositions pour le traitement de maladie en utilisant l'inhalation
JP2013530423A JP2013538830A (ja) 2010-09-27 2011-09-27 吸入を用いる疾患治療のための方法及び組成物
CA2812952A CA2812952A1 (fr) 2010-09-27 2011-09-27 Procedes et compositions pour le traitement de maladie en utilisant l'inhalation

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US38677110P 2010-09-27 2010-09-27
US38676710P 2010-09-27 2010-09-27
US38673310P 2010-09-27 2010-09-27
US38677610P 2010-09-27 2010-09-27
US61/386,767 2010-09-27
US61/386,733 2010-09-27
US61/386,771 2010-09-27
US61/386,776 2010-09-27

Publications (2)

Publication Number Publication Date
WO2012047674A2 true WO2012047674A2 (fr) 2012-04-12
WO2012047674A3 WO2012047674A3 (fr) 2012-05-24

Family

ID=45871251

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/053513 WO2012047674A2 (fr) 2010-09-27 2011-09-27 Procédés et compositions pour le traitement de maladie en utilisant l'inhalation

Country Status (5)

Country Link
US (1) US20120077786A1 (fr)
EP (1) EP2621588A4 (fr)
JP (1) JP2013538830A (fr)
CA (1) CA2812952A1 (fr)
WO (1) WO2012047674A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013026558A3 (fr) * 2011-08-19 2013-04-11 Joy Development Ug Agent de polythérapie
US8807131B1 (en) 2013-06-18 2014-08-19 Isonea Limited Compliance monitoring for asthma inhalers

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3067046B1 (fr) 2005-12-08 2020-03-25 Insmed Incorporated Compositions a base de lipide d'anti-infectieux pour traiter des infections pulmonaires
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
RU2501582C1 (ru) * 2012-10-22 2013-12-20 Государственное бюджетное образовательное учреждение дополнительного профессионального образования "Новокузнецкий государственный институт усовершенствования врачей" Министерства здравоохранения и социального развития Российской Федерации Способ лечения острых пневмоний у ослабленных больных в условиях промышленного города
EP2918290B1 (fr) 2012-11-08 2020-09-02 Yamaguchi University Agent thérapeutique pour troubles kératoconjonctifs
CA2891487A1 (fr) 2012-11-29 2014-06-05 Insmed Incorporated Formulations de vancomycine stabilisees
EP2938329A4 (fr) * 2012-12-27 2016-08-10 Microdose Therapeutx Inc Procédés et compositions pour l'administration d'oxybutynine
EP3446690A1 (fr) 2013-05-22 2019-02-27 Yamaguchi University Inhibiteur de troubles rétinochoroïdaux
WO2015054280A1 (fr) 2013-10-08 2015-04-16 Lam Therapeutics, Inc. Rapamycine pour le traitement de la lymphangioléiomyomatose
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US20150265582A1 (en) * 2014-02-11 2015-09-24 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
EP4218742A1 (fr) 2014-04-04 2023-08-02 AI Therapeutics, Inc. Préparation à inhaler contenant de la rapamycine pour traiter les pathologies liées à l'âge
DK3466432T3 (da) 2014-05-15 2020-09-28 Insmed Inc Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner
KR20170095807A (ko) 2014-10-07 2017-08-23 램 테라퓨틱스, 인코포레이티드 폐 고혈압의 치료를 위한 흡입가능 라파마이신 제제
US20170050945A1 (en) * 2015-07-24 2017-02-23 Insmed Incorporated Compositions and methods for the treatment of sarcoidosis
RU2609992C1 (ru) * 2016-02-02 2017-02-07 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ВГМУ им. Н.Н. Бурденко Минздрава России) Способ улучшения отхождения мокроты
RU2609274C1 (ru) * 2016-02-02 2017-02-01 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ВГМУ им. Н.Н. Бурденко Минздрава России) Способ лечения хронической обструктивной болезни легких
EP4249490A3 (fr) 2016-06-08 2023-12-13 Clementia Pharmaceuticals Inc. Méthodes pour le traitement de l'ossification hétérotopique
EP3525855A4 (fr) * 2016-10-11 2020-06-17 MicroDose Therapeutx, Inc. Inhalateur et procédés d'utilisation associés
WO2018070819A1 (fr) * 2016-10-14 2018-04-19 제주대학교 산학협력단 Composition comprenant du ciclésonide destinée à inhiber la croissance de cellules souches cancéreuses
KR20190100187A (ko) 2016-11-16 2019-08-28 클레멘티아 파마슈티컬즈, 인크. 다중 골연골종(mo)을 치료하는 방법
WO2019191627A1 (fr) 2018-03-30 2019-10-03 Insmed Incorporated Procédés pour la fabrication continue de produits médicamenteux liposomaux
US11925606B2 (en) * 2020-01-17 2024-03-12 Sami-Sabinsa Group Limited Compositions for managing chronic obstructive pulmonary disease
US11253534B2 (en) 2020-03-23 2022-02-22 Sabine Hazan Method of preventing COVID-19 infection
US11744866B2 (en) 2020-03-18 2023-09-05 Sabine Hazan Methods of preventing and treating COVID-19 infection with probiotics
US11278520B2 (en) 2020-03-31 2022-03-22 Sabine Hazan Method of preventing COVID-19 infection
US11903952B2 (en) * 2020-05-27 2024-02-20 Northwestern University Vitamin D as an immune modulator to prevent immune-related complication from COVID-19 infection
WO2022016150A1 (fr) * 2020-07-17 2022-01-20 Ross Peter M Procédés pour le traitement de syndromes de libération de cytokine
FR3128117A1 (fr) * 2021-10-15 2023-04-21 Institut National De Recherche Pour L'agriculture L'alimentation Et L'environnement Combinaison d’E . faecalis et d’un agent anti-inflammatoire et ses utilisations dans la prévention et/ou traitement des maladies respiratoires

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9203535D0 (en) * 1992-02-19 1992-04-08 Leo Pharm Prod Ltd Novel treatment iii
AU1022999A (en) * 1997-09-08 1999-03-29 F. Hoffmann-La Roche Ag 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analogs
WO2000061233A2 (fr) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methodes et compositions de traitement et de prevention de maladies pulmonaires
AU2004247108A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc Treatment of immune-mediated disorders with active vitamin D compounds alone or in combination with other therapeutic agents
US7915242B2 (en) * 2004-02-17 2011-03-29 Wisconsin Alumni Research Foundation Vitamin D receptor antagonists and their use in treating asthma
WO2006100285A1 (fr) * 2005-03-23 2006-09-28 Bioxell Spa Utilisation de composes a base de vitamine d pour traiter l'endometriose
US20060293261A1 (en) * 2005-06-24 2006-12-28 Taisho Pharmaceutical Co., Ltd. Clarithromycin or a salt thereof for the treatment or prevention of pulmonary disorders caused by the destruction of pulmonary alveoli
ES2389231T3 (es) * 2005-12-21 2012-10-24 Meda Pharma Gmbh & Co. Kg Combinación de anticolinérgicos, glucocorticoides y agonistas de beta2 para el tratamiento de enfermedades inflamatorias
TW200817047A (en) * 2006-04-03 2008-04-16 Teva Pharma Drug microparticles
JP2009537530A (ja) * 2006-05-15 2009-10-29 ウィスコンシン・アルムニ・リサーチ・ファウンデーション １α，２５−ジヒドロキシビタミンＤ３の肺送達および副甲状腺ホルモンまたはカルシトニンの同時投与
US20100209536A1 (en) * 2006-09-26 2010-08-19 The Brigham And Women's Hospital, Inc. Methods and Kits for Use in the Treatment and Prevention of Diseases or Conditions of the Immune System or Infectious Diseases
GB0700972D0 (en) * 2007-01-18 2007-02-28 Imp Innovations Ltd Treatment of inflammatory disease
WO2008100539A1 (fr) * 2007-02-12 2008-08-21 Michalis Nicolaou Traitement de la maladie pulmonaire obstructive chonique (mpoc), du reflux gastro-oesophagien pathologique (gerd), des allergies alimentaires et autres affections et troubles gastro-intestinaux attenues par une gestion appropriee de l'histamine au moyen d'une combinaison d'inhibiteurs d'histidine decarboxylase, de medicamen
GB2468073B (en) * 2008-02-26 2012-09-05 Elevation Pharmaceuticals Inc Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
CN102247384A (zh) * 2010-05-19 2011-11-23 天津金耀集团有限公司 含有骨化三醇和丙酸氟替卡松的吸入制剂及其制备方法
EP2723330B1 (fr) * 2011-08-19 2015-07-08 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft mbH Agent de polythérapie contenant des vasoconstricteurs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP2621588A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013026558A3 (fr) * 2011-08-19 2013-04-11 Joy Development Ug Agent de polythérapie
US8807131B1 (en) 2013-06-18 2014-08-19 Isonea Limited Compliance monitoring for asthma inhalers

Also Published As

Publication number Publication date
US20120077786A1 (en) 2012-03-29
CA2812952A1 (fr) 2012-04-12
WO2012047674A3 (fr) 2012-05-24
EP2621588A2 (fr) 2013-08-07
JP2013538830A (ja) 2013-10-17
EP2621588A4 (fr) 2014-09-03

Similar Documents

Publication Publication Date Title
US20120077786A1 (en) Methods and compositions for disease treatment using inhalation
ES2913095T3 (es) Compuestos de pirfenidona y análogos de piridona en aerosol y usos de los mismos
JP5863641B2 (ja) 濃縮肥満細胞安定化用薬学的調合物
US20210330635A1 (en) Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection
CN103501781B (zh) 吡咯糖用于治疗心动过速的用途
PT2506844T (pt) Combinações de um antagonista do recetor muscarínico e um agonista do adrenorrecetor beta-2
JP6066350B2 (ja) エアロゾルボーラスとしてのイロプロストの投与
US20230158259A1 (en) Products of manufacture and methods for treating, ameliorating or preventing microbial infections
US20140113888A1 (en) Novel Combination of Therapeutic Agents
AU2015261103A1 (en) Combinations of tiotropium bromide, formoterol and budesonide for the treatment of COPD
TW200524615A (en) Aqueous suspensions of ciclesonide for nebulisation
US8877740B2 (en) Compound composition for inhalation used for treating asthma
US20100285139A1 (en) Pharmaceutical composition for the prophylaxis and/or symptomatic treatment of cystic fibrosis
US20050053553A1 (en) Combined doses of formoterol and fluticasone
US9795561B2 (en) Combination of umeclidinium, fluticasone propionate and salmeterol xinafoate for use in the treatment of inflammatory or respiratory tract diseases
TWI436761B (zh) 使用噻唑衍生物之方法
KR20170102899A (ko) 약학적 조합물
TW202241457A (zh) 用於預防病毒及微生物感染及其等之後遺症之藥物、治療組合、及方法
CN113038941A (zh) 用于通过肺部施用治疗抑郁症的方法中的氯胺酮组合物
US20050042175A1 (en) Combined doses of formoterol and budesonide
US20220168297A1 (en) Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis, pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and pulmonary arterial hypertension
McCarthy et al. Introduction to Pharmacology of the Lung from a Drug Delivery Perspective
WO2023003593A1 (fr) Formulations de biguanide pulmonaire
CN115666510A (zh) 用于治疗或预防病毒感染的氯法齐明组合物和方法
CN113456618A (zh) 一种复方双嘧达莫的吸入制剂及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11831316

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013530423

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2812952

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011831316

Country of ref document: EP